Ductal carcinoma In-Situ in turner syndrome patient undergoing hormone replacement therapy: A case report by Bawa, Rashmi et al.
International Journal of Cancer Therapy and Oncology
www.ijcto.org
Corresponding author: Rashmi Bawa; Department of Surgery, Pine Health Services, Maine, USA.
Cite this article as: Bawa R, Matemavi P, Maizlin I, Sung KJ. Ductal carcinoma in-situ in Turner syndrome patient undergoing hormone
replacement therapy: A case report. Int J Cancer Ther Oncol. 2016; 4(1):4113. DOI: 10.14319/ijcto.41.13
© Bawa et al. ISSN 2330-4049
Ductal carcinoma in-situ in Turner syndrome patient undergoing
hormone replacement therapy: A case report
Rashmi Bawa1, Praise Matemavi2, Ilan Maizlin2, Kap-Jae Sung2
1Department of Surgery, Pine Health Services, Maine, USA
2Department of Surgery, New York Presbyterian Queens Hospital/Weill Cornell Medical College, New York, USAReceived October 01, 2015; Revised January 17, 2016; Accepted January 18, 2016; Published Online February 06, 2016
Case Report
AbstractTurner’s syndrome is a rare congenital disease which affects about 1 in every2500-3000 live-born females. This happens due to chromosomal abnormalities in aphenotypic female, causing increased gonadotropin concentrations and lowconcentrations of estrogens from infancy. As a result, hormone replacement therapyis started in most adolescent Turner syndrome patients to initiate and sustainsexual maturation. Accordingly, most Turner’s syndrome patients undergo severaldecades of estrogen replacement therapy, from puberty to post-menopausal age.The highly publicized findings of the Women’s Health Initiative have called intoquestion the appropriateness of hormone replacement therapy in adolescents withTurner’s syndrome. Those concerns were mostly theoretical extrapolations, as fewprospective studies of cancer occurrence in women with Turner syndrome havebeen reported. Consequently, several recent publications have challenged thoseextrapolations, based on the assertion that the levels of hormone replacement inTurner syndrome patients are well below the physiologic levels observed in normalmenstruating women, as well as the fact that these women are significantly youngerthan those studied by the Women’s Health Initiative. In discord to those reports, wepresent a case of ductal carcinoma in-situ in a 40-year-old Turner patient, who hadundergone over two decades of combined hormone replacement therapy. Thepatient underwent an elective excisional biopsy for a palpable mass, withhistopathology revealing a complex fibroadenoma with a nidus of ductal carcinomain-situ. The lesion was noted to be estrogen receptor positive and progesteronereceptor negative, with heavy staining for HER-2/Neu receptor. The patient wastreated with tamoxifen. While a rare case, it is imperative for the astute clinician tokeep in mind the consequences of long-term hormone replacement therapy inTurner’s syndrome patients in order to avoid missed diagnosis of breast cancer foroptimum management of these patients.
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1. IntroductionTurner’s syndrome (TS), a rare congenital diseaseaffecting about 1 in every 2500-3000 live-born females.1TS is the result of chromosomal abnormalities in aphenotypic female. These patients have characteristicclinical features and specific somatic abnormalities, themost consistent being short stature, ovarian dysgenesiswith concomitant primary amenorrhea2. Complete 45,Xmonosomy accounts for 40-60% of the karyotypes,whereas 5-10% of patients have a duplication of the longarm of one X (isochromosome Xq) and most of theremaining karyotypes show a mosaicism.2 The
consequent phenotype is thought to be the result ofhaploinsufficiency of genes on the X chromosome thatescape X-inactivation in early embryogenesis.3 Womenwith Turner syndrome have increased gonadotropinconcentrations from infancy and low concentrations ofestrogens. As a result, hormone replacement therapy(HRT) is started in most adolescent Turner syndromepatients to initiate and sustain sexual maturation.4 HRTis usually maintained throughout the patient’s adult life.It is crucial to the maintenance of tissue and boneintegrity and has positive effects on the development of
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patients with TS.5 Accordingly, most TS patients undergoseveral decades of estrogen replacement therapy, frompubertal to post-menopausal age.The highly publicized findings of the Women’s HealthInitiative (WHI) have revealed the risks of combinedprogestin–estrogen therapy in postmenopausal women,including increased risk of certain neoplasms, such asendometrial and breast malignancies.4 More specifically,It has been reported that there is an increased risk ofbreast cancer in healthy postmenopausal women whoreceive more than 5 years of HRT.6 The extrapolation ofthese findings to younger women has called intoquestion the appropriateness of HRT in adolescents withTS. Those concerns and generalizations were theoreticalas few prospective studies of cancer occurrence inwomen with Turner syndrome have been reported.7Moreover, several recent publications4,8 have challengedthese claims that long-term hormone-replacementtherapy does not increase the risk of breast cancer inwomen with TS. The authors of those publications basetheir assertions on the fact that the levels of hormonereplacement in TS are well below the physiologic levelsobserved in normal menstruating women and in womenreceiving oral contraceptives.4 Similarly, they claim thatthe mean age of WHI subjects was 63 years, while it isunclear whether these findings are applicable to ayounger population.8In discord to those reports, we present a case of ductalcarcinoma in-situ (DCIS) in a 40-year-old Turner patient,who had undergone over two decades of combined
hormone replacement therapy and was found to haveleft breast ductal carcinoma in-situ. While a rare case, itis imperative for the astute clinician to keep in mind theconsequences of long-term hormone replacementtherapy in Turner’s syndrome patients to avoid delay indiagnosis and treatment of breast cancer and for theoptimum management of these patients.
2. Case presentation40-year-old female diagnosed with Turner syndrome atthe age of 13, started on hormonal therapy withestrogen and progesterone at the age of 16 years forgrowth and development with appropriate pubertaldevelopment by 17 years of age. She was diagnosed withstreak ovaries and underwent bilateral oophorectomyfor increased risk of ovarian cancer. The patientcontinued on long term hormonal replacement therapyfor 23 years.The patient presented to our Breast Center forevaluation after she noted a palpable lump in the upperouter quadrant of the left breast. She denied any priorhistory of palpable breast masses or abnormal findingson routine mammographic or ultrasound screeningstudies. There was no associated breast pain ortenderness, as well as any recent or remote history oftrauma to the breast. Mammographic and ultrasoundinvestigations during initial work-up demonstrated asmooth solid mass in the left upper, outer quadrant,approximately 2.5 cm in diameter (Figure 1).
Figure 1: Left Mammogram left breast smooth solid mass, right left breast ultrasound 2.5 cm heterogeneous mass.
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Figure 2: H&E histology of the breast lesion demonstrating(a) fibroadenoma with a nidus of ductal carcinoma in-situof solid type (10x magnification), with (b) apocrine andclear cell features and intermediate nuclear grade (40xmagnification).The patient underwent an elective excisional biopsy,during which the lesion was removed en-masse withappropriate gross margins. She tolerated the procedurewell and her recovery was uneventful.Pathology came back as fibroadenoma with DCIS (Figure2). After counselling the patient about treatment optionsa decision was reached to start her on tamoxifen.Radiation therapy was considered and discussed at thefacility’s multi-disciplinary oncological conference butthere was no evidence to support benefit for DCIS thatwas confined to the fibroadenoma with an appropriatenegative margin. The patient did well with tamoxifen. Attwo year follow up, the patient has no recurrence ofdisease clinically and radiologically.
2.1 Pathological featuresThe resection specimen consisted of one irregular pieceof fibrous, fatty breast tissue measuring 4.2 × 3.4 × 2.0cm. Histology confirmed a complex fibroadenoma, withserial sections revealing an extensive pink-white,indurated fibrous area (Figure 2) measuring 3.0 cm ingreatest dimension, with the remainder of the cutsdemonstrating yellow, lobular fatty tissue. Thefibroadenoma was initially considered to be secondarilyinvolved with atypical ductal hyperplasia. However,when the slides of atypical ductal hyperplasia werestained with both routine H&E (Hematoxylin and eosin)staining and immunostaining for androgen receptor,review of those slides (Figure 3) confirmed the presenceof DCIS.
Figure 3: Immunohistochemistry of the breast lesiondemonstrating heavy (+2) staining of the tissue forHER-2/Neu at both (a) 10x magnification and (b) 40xmagnification.The lesion was present as a single 3-4 mm sized focuswithin the complex fibroadenoma and > 2 mm from thenearest surgical margin. The DCIS was noted to have asolid type architectural pattern with apocrine and clearcell features and intermediate nuclear grade. No comedohistology was noted on any of the slides.Immunohistochemical studies performed on the tissuedemonstrated over 95% of the cells to be estrogenreceptor (ER) positive, while less than 5% progesteronereceptor (PR) positive. In addition, the sampledemonstrated heavy staining for HER-2/Neu receptor(Figure 3).
3. DiscussionThe risk of cancer in women with Turner syndrome hasbeen little studied.1 Yet it is an important area forconsideration, because the hormonal abnormalities andtreatments associated with this syndrome might affectthe risk of hormone-related cancers. Moreover, thechromosomal abnormality itself might affect cancer risk.Knowledge of this risk is also important for patient andfamily education on the disease and its prognosticimplications, and for clinical and screening practiceduring the follow-up of these patients.7One might consider that the risk of breast cancer in TSpatients would be relatively decreased, consideringunderdevelopment of breast tissue in most Turnerpatients and low endogenous estrogen concentrations.3
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That assumption was factually confirmed in a recentstudy published by Schoemaker et al.7, whodemonstrated that TS patients in their cohort hadsignificantly decreased rates of breast neoplasms ascompared with that of the general population. It isimportant to note, however, that the studied TS patientshad only endogenous hormone levels, none havingundergone HRT. The question of breast malignancies inthe setting of long-term HRT remains therefore,uninvestigated in large-scale population studies.This issue becomes relevant in the setting of the WHItrial results6, where hormone replacement therapy ingeneral has been called into question. While the WHIstudy investigated healthy postmenopausal female ashaving an increased risk of breast cancer in women whoreceived more than 5 years of HRT, its results wereapplied to all women regardless of age or hormonalstatus. Recent studies by Bösze et al.8, as well as byWarren et al.4, claimed this to be an inappropriateextrapolation. They point out that levels of estrogen andprogesterone in TS patients undergoing HRT are muchlower than in normal menstruating woman of similarage group. Especially since the use of oralcontraceptives, which are much higher in estrogencontent, have not shown the same risk.9 Similarly, theyclaim that the risks cannot be extended to adolescentsand young adults with TS, given the difference in agebetween the populations and the relative risks versusbenefits of hormone replacement therapy for each agegroup. Since women with TS, who are denied exposureto sex hormones have substantial risk or morbidity inthe areas of growth, osteoporosis, and psychosocialdevelopment, these authors advocate for generalizedintroduction of HRT among individuals with TS.4,8In light of those studies, we find it especially importantto publish our case as it demonstrates a unique case ofbreast malignancy in a Turner patient on long-term HRT.Consequently, as it appears in a patient meant to be atvery low risk for such a malignancy, it raises importantconcerns in relation to plausible causality between HRTand breast neoplasms. The astute clinician must,therefore, be aware and exercise appropriate level ofclinical suspicion in this otherwise protected population.
4. ConclusionAs adolescents with TS approach menopausal age, andas more long-term data become available, estrogen-progesterone replacement risks and benefits maybecome clearer. As such, our case report might be asentinel event demonstrating that long-term hormonereplacement in these individuals carries a higher risk ofbreast malignancies and pre-malignant lesions than
previously considered. We propose that further studiesare needed to explore the possible risk of long-termhormone replacement therapy as an underlying cause ofbreast neoplasms in TS patients.
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